Form 144 is an advance notice of intent to sell, not a completed transaction. Monitor for a subsequent Form 4 filing to confirm actual sale. The exercise of options and sale by a director is routine and not indicative of material negative news.
Price Chart
Executive Summary
Director Christopher Starr filed a Form 144 notice of intent to sell 16,800 shares of Monopar Therapeutics common stock, with an estimated aggregate market value of approximately $1.34 million. The shares would be acquired upon exercise of stock options, and the sale is planned to occur over the next three months. This is a routine insider sale by a director exercising options, not a large proportion of the company's float, and carries limited signaling weight.
Key Facts
- Insider: Christopher Starr, Director of Monopar Therapeutics
- Shares to be sold: 16,800 shares of common stock
- Estimated aggregate market value: $1,338,456
- Sale method: open market via Morgan Stanley Smith Barney LLC
- Source of shares: exercise of stock options (acquired from issuer)
- Filing date: October 1, 2026
- Sale planned over the next three months
Financial Impact
Proposed sale of 16,800 shares valued at ~$1.34 million; represents a modest portion of the insider's holdings and a small fraction of the company's market cap.
Risk Factors
- Insider may not complete the sale; Form 144 is only an intent notice.
- If the sale is completed, it could signal insider desire for liquidity, but the amount is small relative to typical director holdings.
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001950047-26-009981 |
| Document: 0001950047-26-009981-index.html | 0001950047-26-009981 |
| Document: 0001950047-26-009981.txt | 0001950047-26-009981 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | Institutional Cluster | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 27, 2026 today | SC 13G | $72.00 | awaiting T+60 | — | $71.84 (−0.22%) |
Oct 5, 2026 22d ago | Insider Cluster | $79.57 | awaiting T+60 | — | $71.84 (+9.71%) |
Oct 1, 2026 26d ago | 144 | $77.97 | awaiting T+60 | — | $71.84 (−7.86%) |
Aug 28, 2026 8w ago | Insider Cluster | $111.93 | awaiting T+60 | — | $71.84 (−35.82%) |
Aug 27, 2026 8w ago | Insider Cluster | $111.89 | awaiting T+60 | — | $71.84 (−35.79%) |
Aug 25, 2026 9w ago | 144 | $113.72 | awaiting T+60 | — | $71.84 (−36.83%) |
Aug 12, 2026 10w ago | 8-K | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Aug 12, 2026 10w ago | Press Release | $114.90 | awaiting T+60 | — | $71.84 (−37.48%) |
Jul 22, 2026 13w ago | 8-K | $112.48 $71.80 | ▼ −36.17% | ▼ −39.43% | $71.84 (−36.13%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers